CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 171 enrolled
Drug / intervention
granisetron +1 moredrug
Likely dose
Granisetron 20 or 40 micrograms intravenously 15 minutes prior to end of surgeryAI-extracted
Key inclusion· 3
  • Age 2–16 years
  • Scheduled elective tonsillectomy or adenotonsillectomy requiring general anesthesia and endotracheal intubation
  • Hospital admission for no longer than 24 hours
Key exclusion· 4
  • Known allergy or contraindication to granisetron (Kytril) or its components
  • Known allergy to any other 5HT3 antagonist
  • History of motion sickness or post-operative nausea and vomiting
  • Nausea or vomiting in the 24 hours prior to anesthesia

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00231478
NCT00231478Phase 4Completed

A Randomized, Double-blind Study of 2 Dose Levels of Kytril on the Prevention of Post-operative Nausea and Vomiting in Pediatric Patients Undergoing Surgery With General Anesthesia

Hoffmann-La Roche·interventional·Posted Oct 4, 2005·Updated Mar 27, 2018

In Brief

A Phase 4 clinical trial evaluating granisetron for Post-Operative Nausea and Vomiting. Completed, enrolled 171 participants across 11 sites.

Detailed Summary

This 2 arm study will evaluate the efficacy and safety of a single intravenous injection of Kytril in preventing postoperative nausea and vomiting (PONV) in children. Patients will be randomized to receive a single dose of either 20 micrograms or 40 micrograms Kytril intravenously (iv) 15 minutes prior to the end of surgery with general anesthesia for tonsillectomy or adenotonsillectomy. The anticipated time on study treatment is \<3 months, and the planned sample size was 170 patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 4, 2005
Enrollment StartApr 1, 2007
Primary CompletionDec 1, 2007
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 20.7 years ago

Interventions

granisetrondrug

20 micrograms intravenously (iv) 15 min prior to end of surgery

granisetrondrug

40 micrograms intravenously (iv) 15 min prior to end of surgery